Related Experiment Video
Updated: Aug 13, 2026
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
Olaparib for the treatment of breast cancer
Marie Robert1, Jean-Sébastien Frenel1, Carole Gourmelon1
1a Medical oncology , Institut de Cancérologie de l'Ouest, René Gauducheau , St Herblain , France.
Introduction:
Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this deficiency through a synthetic lethality and are considered as promising anticancer therapies, especially in patients harboring BRCA1 or BRCA 2 mutations. Areas covered: Olaparib is one of the most widely investigated PARP inhibitors. Here, the preclinical data, completed clinical trials and ongoing investigations are discussed. Expert opinion: PARP inhibitors show promising results in breast cancer. However, several issues are raised including the identification of biomarkers to predict treatment response and strategies to counteract emerging resistance. Moreover, the results from ongoing phase III trials of olaparib in breast cancer are still awaited.
Insights
PARP inhibitors like olaparib show promise for treating aggressive triple-negative breast cancer by targeting DNA repair defects. Further research is needed to identify biomarkers and overcome resistance for optimal patient outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Basal-like breast cancer is aggressive and often triple-negative.
- DNA repair defects, particularly BRCA alterations (11-42%), are common in these tumors.
- PARP inhibitors offer a targeted therapy exploiting these DNA repair deficiencies.
Purpose of the Study:
- To review preclinical data, clinical trials, and ongoing research on the PARP inhibitor olaparib.
- To discuss the potential of olaparib in treating basal-like breast cancer.
Main Methods:
- Review of preclinical studies on olaparib.
- Analysis of completed and ongoing clinical trials involving olaparib.
- Discussion of expert opinions on PARP inhibitor therapy.
Main Results:
- Olaparib is a widely investigated PARP inhibitor with promising preclinical and clinical data.
- PARP inhibitors demonstrate potential as anticancer therapies, especially for BRCA-mutated breast cancers.
Conclusions:
- PARP inhibitors show promise in breast cancer treatment.
- Key challenges include identifying predictive biomarkers and managing treatment resistance.
- Results from ongoing Phase III trials of olaparib are anticipated.
More Related Videos
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
07:53Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers